Why is Hims & Hers Health stock up today?

Traders Union
All News
Financial News
Hims & hers health rises 2.02% today

Highlights

Hims & Hers Health posted a Q1 adjusted loss per share of $0.18, swinging from prior-year profitability.
Monthly online revenue per average subscriber dropped 5.9% to $80, reflecting operational changes in shipping frequency.
Despite short-term bullish momentum, overbought technical signals and weak long-term structure suggest a likely rangebound move between $25.85 and $29.88.

Revenue outlook raised as subscriber spending and profit metrics weaken

Hims & Hers Health reported a quarterly adjusted loss per share of $0.18 for the first quarter of 2026, reversing from a $0.20 adjusted profit in the same period last year. The company also saw its monthly online revenue per average subscriber decline 5.9% year over year to $80, attributed to operational changes in shipping frequency for selected products. Despite these challenges, full-year revenue guidance was raised to a range of $2.8 billion to $3 billion, reflecting confidence in continued top-line growth while addressing impacts on profit and recurring revenue metrics.

Anton Kharitonov, expert at Traders Union, sees risk building for Hims & Hers Health despite the recent share price bounce. The short-term bullish momentum clashes with overbought technicals and a weak long-term setup below the 200-day average. He points out the reversal from an adjusted profit to loss per share, as well as the drop in recurring subscriber revenue — both clear warning signs. Oscillators are flashing signals of exhaustion, while volatility remains elevated. As Kharitonov says, "The technical and fundamental backdrop warrants caution — any break below $25.85 could accelerate a pullback."

Viktoras Karapetjanc, expert at Traders Union, maintains a constructive view of HIMS. He notes the raised revenue guidance and resilient upward structure despite temporary profitability pressure. Karapetjanc highlights how operational optimizations open new growth avenues while medium-term technicals remain supportive. The ongoing demand and bullish tone set the stage for further gains once consolidation ends. He concludes, "Structurally, the bullish setup remains intact and I expect the next sustainable push will be upward once overbought signals reset."

Intraday bullish momentum diverges from overbought risk and weak trend

Support for HIMS is indicated by the Ichimoku Kijun at $25.96, with immediate resistance likely at the recent swing high around $28.50. Momentum indicators are mixed: the MACD on the daily chart remains positive, reinforcing upward momentum, but the ADX signals a weak overall trend. The RSI at 56.04 is leaning bullish, yet both the Stochastic RSI and CCI are overbought, raising the risk of a short-term pullback. Bull/Bear Power (BBP) is firmly positive at 2.88, clearly showing buyers dominate intraday activity but is also in overbought territory. The Awesome Oscillator supports the current upward trend. The stock opened with a downside gap of about $0.48 but quickly reclaimed ground, now trading at the high end of today's $26.75 – $28.25 range, with intraday volatility at 5.61% and a strong upward tone. A divergence is emerging between robust short-term momentum and overbought oscillators.

Earlier, analysts noted that Hims & Hers Health exhibited mixed technical momentum, with medium-term bullish signals challenged by short-term and long-term uncertainties. With current trading action strengthening short-term momentum but highlighting overbought conditions, traders should closely monitor for potential volatility spikes or a reversal should momentum indicators begin to roll over in the coming sessions.

Source of Data: HIMS Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.